Dapagliflozin/saxagliptin


Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2][3] It is a combination of dapagliflozin and saxagliptin.[2][3] It is taken by mouth.[2][3]

Dapagliflozin/saxagliptin
Combination of
DapagliflozinSGLT-2 inhibitor
SaxagliptinDipeptidyl peptidase-4 inhibitor
Clinical data
Trade namesQtern
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: D [1]
  • US: N (Not classified yet) [1]
    Routes of
    administration    		By mouth
    ATC code
    Legal status
    Legal status
    Identifiers
    KEGG

    The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]

    Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]

    Medical uses

    In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2]

    In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

    • to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.[3]
    • when already being treated with saxagliptin and dapagliflozin.[3]
    gollark: Transistors are not widely considered diodes.
    gollark: How do you diodeuously do AND?
    gollark: 14.2 billion. You need a computer to run the OR gate on.
    gollark: I think generally petroleum gas demand outpaces the rest, so it "works".
    gollark: I generally have a circuit network thing run cracking plants if I have too much heavy/light oil.

    References
    1. "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Retrieved 14 July 2020.
    2. "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 14 July 2020.
    3. "Qtern EPAR". European Medicines Agency (EMA). Retrieved 14 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
    4. "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 14 July 2020.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.